Table 1. Patient demographics at DB trial baseline.
| J-RAPID |
HIKARI |
|||
|---|---|---|---|---|
| Characteristic | LD group (n = 82) | No-LD group (n = 61) | LD group (n = 116) | No-LD group (n = 99) |
| Mean age, years (SD) | 50.6 (11.4) | 51.7 (11.7) | 56.0 (10.2) | 55.2 (9.7) |
| Female, n (%) | 69 (84.1) | 54 (88.5) | 83 (71.6) | 78 (78.8) |
| Mean body weight, kg (SD) | 56.3 (11.3) | 55.6 (12.6) | 57.5 (11.7) | 56.9 (10.1) |
| Mean disease duration, years (SD) | 5.6 (4.2) | 6.0 (4.0) | 5.4 (4.0) | 5.8 (4.4) |
| Mean no. of prior DMARDs, including MTX (SD) | 1.7 (0.8) | 0.7 (0.9) | 1.9 (1.0) | 1.1 (0.9) |
| Mean MTX dose, mg/week (SD) | 7.6 (0.8) | 7.4 (0.9) | – | – |
| DMARDs at baseline, n (%) | – | – | 62 (53.4) | 55 (55.6) |
| Baseline corticosteroid use, n (%) | 56 (68.3) | 37 (60.7) | 77 (66.4) | 70 (70.7) |
| Prior anti-TNF use, n (%) | 11 (13.4) | 15 (24.6) | 8 (6.9) | 13 (13.1) |
DMARD, disease-modifying antirheumatic drug; LD, loading dose; MTX, methotrexate; SD, standard deviation; TNF, tumor necrosis factor.